GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell ...
VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...
Ross Memorial Hospital in Kawartha Lakes, Ontario, Canada, is set to undergo the expansion and renovation of its emergency ...
MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the ...
RAHWAY, NJ, USA I 14, 2024 I Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately ...
Investor's Business Daily on MSN18h
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit TherapeuticsMerck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based ...
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...
Merck (MRK) and LaNova Medicines, a privately held clinical-stage biotechnology company, announced that Merck has entered into an exclusive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback